Core Viewpoint - Hong Kong's biopharmaceutical stocks experienced a significant afternoon rally, indicating positive market sentiment in the sector [2] Group 1: Stock Performance - Yongtai Bio-B surged over 12% [2] - Keji Pharmaceutical-B increased nearly 10% [2] - Tiansheng Pharmaceutical-B rose over 5% [2] - WuXi AppTec-B and Weisheng Pharmaceutical-B both gained over 3% [2]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (科济药业-B) has seen a significant increase in stock price, attributed to the upcoming presentation of clinical data for CT0596 at the 67th American Society of Hematology (ASH) annual meeting and the recent approval of its CAR-T drug for inclusion in insurance directories [1]. Group 1: Stock Performance - Kintor Pharmaceutical's stock price rose over 7% during trading, with a current increase of 5.70%, reaching HKD 19.85 [1]. - The trading volume amounted to HKD 13.3487 million [1]. Group 2: Clinical Data Presentation - The company announced that it will present clinical data for its drug CT0596 at the ASH annual meeting [1]. Group 3: Regulatory Developments - On September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the commercial insurance innovative drug directory [1]. - Kintor's CAR-T drug, Sai Ke Ze, along with four other CAR-T drugs, successfully passed the expert review, indicating a potential inclusion in this year's basic medical insurance directory and commercial insurance innovative drug directory [1].

Group 1 - Kintor Pharmaceutical (科济药业-B) shares rose over 7%, currently up 6.39% at HKD 19.98, with a trading volume of HKD 10.51 million [1] - The company announced it will present clinical data for CT0596 at the 67th American Society of Hematology (ASH) annual meeting [1] - On September 20, the National Healthcare Security Administration announced the completion of expert review for the first version of the commercial insurance innovative drug catalog, with Kintor's CAR-T drug, Sai Ke Ze, among five CAR-T drugs that passed the review, potentially entering this year's basic medical insurance and commercial insurance innovative drug catalog [1]

Group 1 - The core point of the article is that Kintor Pharmaceutical (科济药业-B) has seen a stock price increase of over 7%, currently trading at 19.98 HKD with a transaction volume of 10.51 million HKD [1] - Kintor Pharmaceutical announced that it will present clinical data for CT0596 at the 67th American Society of Hematology (ASH) annual meeting [1] - On September 20, the National Healthcare Security Administration announced the completion of expert review for the first version of the commercial insurance innovative drug catalog, with Kintor's CAR-T drug, Sai Ke Ze, among five CAR-T drugs that passed the review, potentially entering the basic medical insurance catalog and commercial insurance innovative drug catalog this year [1]

Core Insights - Company Kintor Pharmaceutical (科济药业-B) announced that it will present clinical data for CT0596, a BCMA-targeted allogeneic CAR-T cell candidate, at the 67th American Society of Hematology Annual Meeting [1] - CT0596 is developed on the company's proprietary THANK-u Plus platform and is currently undergoing investigator-initiated clinical trials for relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL) [1] - The candidate has shown promising safety and efficacy signals, with CAR-T cell expansion observed across all predefined dose groups [1] - The company plans to explore CT0596 in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells [1] - An IND application for CT0596 is expected to be submitted in the second half of 2025 [1]

Core Viewpoint - Company Kintor Pharmaceutical (科济药业-B) is set to present clinical data for its CAR-T cell therapy candidate CT0596 at the 67th American Society of Hematology Annual Meeting, with further details to be released on November 3, 2025 [1] Group 1: Product Information - CT0596 is a universal CAR-T cell therapy targeting BCMA, developed on the company's proprietary THANK-u Plus™ platform [1] - The therapy is currently undergoing investigator-initiated clinical trials for relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL) [1] - Initial results indicate promising safety and efficacy signals, with CAR-T cell expansion observed across all predefined dose groups [1] Group 2: Future Plans - In addition to R/R MM, the company plans to explore CT0596 in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells [1] - The company anticipates submitting an IND application for CT0596 in the second half of 2025 [1]

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 科濟藥業是一家生物製藥公司，專注於開發創新CAR-T細胞療法，以滿足未滿足 的臨床需求，包括但不限於血液惡性腫瘤、實體瘤及自身免疫性疾病。科濟藥業 建立了從靶點發現、臨床前研究、產品臨床開發到商業規模生產的CAR-T細胞研 究與開發的端到端能力。科濟藥業通過自主研發新技術以及擁有全球權益的產品 管線，以解決現有CAR-T細胞療法的挑戰，比如提高安全性、提高治療實體瘤的 療效和降低治療成本等。科濟藥業的使命是成為全球生物製藥領域的領導者，為 全球癌症及其他疾病的患者提供創新和差異化的細胞療法，使癌症及其他疾病可 治癒。 1 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 自願公告 於2025年ASH年會上呈列的CT0596的研究成果更新 本公告由科濟藥業控股有限公司（「本公司」 ...

Core Viewpoint - Pharmaceutical stocks are under pressure following the announcement of new tariffs on imported pharmaceutical products by U.S. President Trump, which could significantly impact the industry [1] Group 1: Stock Performance - Companies such as 科济药业-B (02171) saw a decline of 5.11%, trading at 18.37 HKD [1] - 康宁杰瑞制药-B (09966) dropped by 3.48%, with a trading price of 12.22 HKD [1] - 维亚生物 (01873) fell by 3.52%, now priced at 2.47 HKD [1] - 泰格医药 (300347) (03347) decreased by 3.1%, trading at 45.6 HKD [1] Group 2: Tariff Announcement - Starting October 1, the U.S. will impose a 100% tariff on all brands and patented pharmaceutical products [1] - Trump indicated that these tariffs will not apply to companies that build factories in the U.S., defining such facilities as "under construction" [1] Group 3: Policy Context - Trump's administration has focused on "lowering drug prices" and "supply chain repatriation" as key themes in its policies affecting the pharmaceutical industry this year [1]

Group 1 - Pharmaceutical stocks are under pressure, with notable declines: 科济药业-B down 5.11% to 18.37 HKD, 康宁杰瑞制药-B down 3.48% to 12.22 HKD, 维亚生物 down 3.52% to 2.47 HKD, and 泰格医药 down 3.1% to 45.6 HKD [1] - On September 25, President Trump announced a new round of high tariffs on various imported products, including a 100% tariff on all brands and patented pharmaceutical products starting October 1 [1] - The tariffs will not apply to companies that build factories in the U.S., defined by Trump as "under construction" [1] Group 2 - Trump's policies this year have focused on the pharmaceutical industry, with key themes being "lower drug prices" and "supply chain repatriation" [1]

科济药业-B(02171)发布公告，公司非执行董事郭炳森先生于2025年9月24日安详逝世。 ...